Tarpeyo (budesonide) is a medication that has been recently studied for proteinuria treatment in adults with primary immunoglobulin A nephropathy (IgAN). Patients with IgAN produce too many antibodies, which damage the kidneys causing proteinuria. The mechanism of how Tarpeyo works isn’t fully understood, but is suggested to reduce inflammation and improve glomeruli function. Clinical trials show Tarpeyo significantly reduces proteinuria; reducing it by 28% in 9 months compared to placebo. Tarpeyo was also found to be as effective as angiotensin converting enzyme (ACE) inhibitors. Possible side-effects include headaches, nausea, thrush, increased infections, osteoporosis, and glaucoma. Patients must be monitored consistently for kidney function and other health indicators.